Parel – With a view to create awareness among Indians on the disease of cancer, Medgenome Company has initiated a new technology called ‘Oncotrack’.
Informing this in a programme held at ITC Grand Central, Medgenome CEO Dr L Ramprasad said that Oncotrack technology is NGS-based Liquid Biopsy Screening Test for cancer treatment monitoring.
Tata Memorial Hospital’s senior oncologist Dr Kumar Abhas, Dr Ramakant Deshpande and Medgenome director Sam Santosh were also present on this occasion.
Share
Tweet
